LeonaBio, Inc. SEC filings LONA
LeonaBio, Inc. has 469 filings in SEC EDGAR's recent list, going back to Oct 3, 2014. Its latest annual report, Form ARS, was filed on May 11, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 1, 2026 | — |
| EFFECT | Filing | Apr 1, 2026 | — |
| CORRESP | Letter to the SEC | Mar 31, 2026 | — |
| CORRESP | Letter to the SEC | Mar 31, 2026 | — |
| DEFR14A | Filing | Mar 10, 2026 | — |
| CORRESP | Letter to the SEC | Feb 20, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2026 | — |
| EFFECT | Filing | Oct 28, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2024 | — |
| CORRESP | Letter to the SEC | Oct 24, 2024 | — |
| DFAN14A | Dfan 14a | May 16, 2022 | — |
| DFAN14A | Dfan 14a | May 12, 2022 | — |
| DFAN14A | Schedule 14a information | May 5, 2022 | — |
| DFAN14A | Dfan 14a | May 4, 2022 | — |
| DFAN14A | Schedule dfan14a - definitive additional materials | May 2, 2022 | — |
| DFAN14A | Schedule 14a information | Apr 27, 2022 | — |
| DFAN14A | Schedule 14a information | Apr 25, 2022 | — |
| DFAN14A | Schedule 14a information | Apr 22, 2022 | — |
| DFAN14A | Schedule 14a information | Apr 13, 2022 | — |
| DFAN14A | Filing | Apr 11, 2022 | — |
| DEFC14A | Filing | Apr 11, 2022 | — |
| PREC14A | Filing | Apr 8, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 6, 2022 | — |
| DEFC14A | Filing | Apr 5, 2022 | — |
| PREC14A | Filing | Mar 30, 2022 | — |
| DFAN14A | Filing | Mar 30, 2022 | — |
| CORRESP | Letter to the SEC | Mar 25, 2022 | — |
| PREC14A | Filing | Mar 25, 2022 | — |
| EFFECT | Filing | Nov 24, 2021 | — |
| CORRESP | Letter to the SEC | Nov 22, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2021 | — |
| EFFECT | Filing | Jan 20, 2021 | — |
| CORRESP | Letter to the SEC | Jan 15, 2021 | — |
| CORRESP | Letter to the SEC | Jan 15, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2021 | — |
| DRS | Filing | Jan 6, 2021 | — |
| EFFECT | Filing | Sep 17, 2020 | — |
| SEC STAFF LETTER | Filing | Sep 17, 2020 | — |
| CORRESP | Letter to the SEC | Sep 17, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 16, 2020 | — |
| CERT | Filing | Sep 16, 2020 | — |
| CORRESP | Letter to the SEC | Sep 14, 2020 | — |
| CORRESP | Letter to the SEC | Sep 14, 2020 | — |
| CORRESP | Letter to the SEC | Sep 14, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 10, 2020 | — |
| 8-A12B | Filing | Sep 9, 2020 | — |
| SEC STAFF LETTER | Filing | Sep 4, 2020 | — |
| CORRESP | Letter to the SEC | Sep 2, 2020 | — |
| CORRESP | Letter to the SEC | Aug 26, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 21, 2020 | — |
| DRS | Filing | Jul 24, 2020 | — |
| DRSLTR | Filing | Jul 24, 2020 | — |
| D | Filing | Jun 12, 2020 | — |
| D/A | Filing | Jan 24, 2020 | — |
| D/A | Filing | Sep 19, 2019 | — |
| D/A | Filing | Jan 23, 2019 | — |
| D | Filing | Dec 20, 2018 | — |
| D/A | Filing | Nov 1, 2017 | — |
| D/A | Filing | Apr 20, 2017 | — |
| D | Filing | Nov 20, 2015 | — |
| D/A | Filing | Feb 5, 2015 | — |
| D | Filing | Oct 3, 2014 | — |
Showing 63 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LONA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1620463
- Former names
- Athira Pharma, Inc. (until Jan 8, 2026); M3 Biotechnology, Inc. (until Jan 23, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.